Your browser doesn't support javascript.
loading
Efficacy and safety of SBRT combined with sintilimab and IBI305 in patients with advanced HCC and previously failed immunotherapy: study protocol of a phase 2 clinical trial.
Zhang, Jinfeng; Yang, Yongqiang; Wu, Zilong; Zhang, Sisi; Lin, Zhenyu; Liu, Hongli; Hu, Jianli; Zhang, Tao; Tang, Jing; Xue, Jun.
Afiliación
  • Zhang J; Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Yang Y; Institute of Radiation Oncology, Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology Cancer Center, Wuhan, China.
  • Wu Z; Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Zhang S; Institute of Radiation Oncology, Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology Cancer Center, Wuhan, China.
  • Lin Z; Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Liu H; Institute of Radiation Oncology, Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology Cancer Center, Wuhan, China.
  • Hu J; Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Zhang T; Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Tang J; Institute of Radiation Oncology, Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology Cancer Center, Wuhan, China.
  • Xue J; Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
BMJ Open ; 14(6): e077903, 2024 Jun 10.
Article en En | MEDLINE | ID: mdl-38858156
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Radiocirugia / Carcinoma Hepatocelular / Anticuerpos Monoclonales Humanizados / Neoplasias Hepáticas Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: BMJ Open Año: 2024 Tipo del documento: Article País de afiliación: China
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Radiocirugia / Carcinoma Hepatocelular / Anticuerpos Monoclonales Humanizados / Neoplasias Hepáticas Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: BMJ Open Año: 2024 Tipo del documento: Article País de afiliación: China